Press releases

Press release2019/10/10

US National Cancer Institute initiates phase I study of treatment of head and neck cancer patients with Medivir’s birinapant and radiation therapy

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in a phase I...

Press release2019/08/28

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2019

April – JuneSignificant events during the quarter Selective effect signal on liver cancer tissue in phase Ia study with MIV-818. The...

Press release2019/06/13

Selective effect signal on liver cancer tissue in phase Ia study with MIV-818

Stockholm, Sweden – Medivir AB (Nasdaq, Stockholm: MVIR) today announces the results of an analysis of data from the first six...

Press release2019/06/04

Medivir to present at the 2019 BIO International Convention

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the 2019 BIO International Convention in...

Press release2019/06/03

New data from the phase I study of birinapant in combination with Keytruda® presented at ASCO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Press release2019/05/27

Medivir to present at the Redeye Pre-ASCO Seminar on May 28

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm....

Press release2019/05/16

New data from the phase I study of birinapant in combination with Keytruda® will be presented at the ASCO 2019

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Press release2019/05/13

Positive data from the remetinostat phase II study in basal cell carcinoma presented at SID Annual meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that positive data from the investigator-initiated study evaluating the effects of...

Press release2019/05/09

Resolutions at the Annual General Meeting in Medivir on 9 May 2019

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing directorThe...

Press release2019/05/07

Data from the remetinostat phase II study in basal cell carcinoma patients to be presented at the 2019 SID Annual meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that data from the investigator-initiated study evaluating the effects of remetinostat...

Press release2019/05/06

Safety and efficacy data from the MIV-711 phase II open label extension study presented at the OARSI world congress

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, has...

Press release2019/05/03

MEDIVIR AB – INTERIM REPORT, JANUARY – MARCH 2019

Clinical studies progress according to plan January – MarchSignificant events during the quarter The phase II study of birinapant in combination...